Lamb, Kieran D. https://orcid.org/0000-0002-3011-5189
Hughes, Joseph https://orcid.org/0000-0003-2556-2563
Lytras, Spyros https://orcid.org/0000-0003-4202-6682
Young, Francesca
Koci, Orges
Herzig, James C.
Lovell, Simon C.
Grove, Joe https://orcid.org/0000-0001-5390-7579
Yuan, Ke https://orcid.org/0000-0002-2318-1460
Robertson, David L. https://orcid.org/0000-0001-6338-0221
Funding for this research was provided by:
RCUK | Medical Research Council (MC_UU_12014/12, MC_UU_00034/6, MC_UU_00034/5, MR/V01157X/1, MR/N013166/1, MR/Y002814/1, MC_PC_19027)
RCUK | Medical Research Council (MR/N013166/1)
RCUK | Medical Research Council (MC_UU_12014/12, MC_UU_00034/5)
RCUK | Medical Research Council (MC_UU_00034/6)
Research Councils UK (MR/W005611/1, MR/Y004205)
Wellcome Trust (220977/Z/20/Z)
RCUK | Biotechnology and Biological Sciences Research Council (BB/V016067/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/V016067/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/V016067/1)
Cancer Research UK (EDDPGM-Nov21\100001, DRCMDP-Nov23/100010, A31287)
Prostate Cancer UK (MA-TIA22-001)
EC | Horizon 2020 Framework Programme (101016851)
Article History
Received: 18 September 2024
Accepted: 27 January 2026
First Online: 19 February 2026
Competing interests
: Ke Yuan is a co-founder and shareholder of TileBio Ltd.